OncoMatch/Clinical Trials/NCT04872790
Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia
Is NCT04872790 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments for b acute lymphoblastic leukemia.
Treatment: Dasatinib · Methotrexate · Prednisone · Rituximab · Venetoclax · Blinatumomab — This phase Ib trial studies the effects of venetoclax in combination with dasatinib, prednisone, rituximab and blinatumomab in treating patients with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL) that is newly diagnosed or that has come back (relapsed). Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Anti-inflammatory drugs, such as prednisone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Rituximab and blinatumomab are monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Giving venetoclax in combination with dasatinib, prednisone, and rituximab and blinatumomab may help treat patients with newly diagnosed or relapsed Philadelphia chromosome positive acute lymphoblastic leukemia.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Biomarker criteria
Required: BCR t(9;22)
diagnosis of B acute lymphoblastic leukemia harboring the t(9;22) translocation (Philadelphia chromosome positive acute lymphoblastic leukemia [Ph+ ALL])
Required: ABL1 t(9;22)
diagnosis of B acute lymphoblastic leukemia harboring the t(9;22) translocation (Philadelphia chromosome positive acute lymphoblastic leukemia [Ph+ ALL])
Required: CD19 expression (positive by flow cytometry on bone marrow if prior CAR T therapy)
Expression of CD19 by flow cytometry on bone marrow, if individual has received prior chimeric antigen receptor (CAR) T therapy
Performance status
ECOG 0–1(Restricted strenuous activity)
Eastern Cooperative Oncology Group (ECOG) status =< 2
Prior therapy
Cannot have received: dasatinib (dasatinib)
Exception: relapsed subjects and newly diagnosed subjects both excluded if prior dasatinib
For newly diagnosed subjects: who have received ... prior dasatinib treatment. For relapsed subjects: prior dasatinib treatment (however treatment with other tyrosine kinase inhibitors [TKIs] is permitted)
Cannot have received: cytotoxic chemotherapy
Exception: newly diagnosed subjects only; steroids, hydrea, or IT methotrexate permitted
For newly diagnosed subjects: who have received treatment with cytotoxic chemotherapy, radiotherapy or immunotherapy for their ALL/MPAL, or prior dasatinib treatment
Cannot have received: radiotherapy
Exception: newly diagnosed subjects only
For newly diagnosed subjects: who have received treatment with cytotoxic chemotherapy, radiotherapy or immunotherapy for their ALL/MPAL, or prior dasatinib treatment
Cannot have received: immunotherapy
Exception: newly diagnosed subjects only
For newly diagnosed subjects: who have received treatment with cytotoxic chemotherapy, radiotherapy or immunotherapy for their ALL/MPAL, or prior dasatinib treatment
Cannot have received: investigational agent
Subjects who have received any investigational agents or subjects who are taking investigational or commercial agents or therapies with the intent to treat the subject's malignancy within seven days or three half-lives of enrollment (i.e. initiation of dasatinib)
Lab requirements
Kidney function
calculated creatinine clearance >= 50 mL/min; determined via urine collection for 24-hour creatinine clearance or by the Cockcroft-Gault formula
Liver function
AST < 2.5 x ULN; ALT < 2.5 x ULN; total bilirubin < 1.5 x ULN (unless considered due to leukemic organ involvement or Gilbert's Syndrome per investigator/AbbVie medical monitor)
Cardiac function
Normal corrected QT Formula (QTcF) interval on screening electrocardiogram (EKG) (< 450 ms regardless of sex)
AST < 2.5 x ULN; ALT < 2.5 x ULN; total bilirubin < 1.5 x ULN... Subject must have adequate renal function as demonstrated by a calculated creatinine clearance >= 50 mL/min... Normal corrected QT Formula (QTcF) interval on screening electrocardiogram (EKG) (< 450 ms regardless of sex)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- OHSU Knight Cancer Institute · Portland, Oregon
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify